Clarivate Epidemiology’s coverage of gout comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of gout for each country, as well as…
The drug market for opioid-induced constipation (OIC) is served by a variety of prescription medications, including several agents that are approved for irritable bowel syndrome with constipation (…
Clarivate Epidemiology’s coverage of diabetic macular edema (DME) comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of DME for each country…
MARKET OUTLOOK Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally…
Clarivate Epidemiology's coverage of male LUTS comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of male LUTS for each…
Clarivate Epidemiology's coverage of benign prostatic hyperplasia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology's coverage of benign prostatic hyperplasia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology's coverage of benign prostatic hyperplasia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of male hypogonadism comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Clarivate Epidemiology's coverage of BPH comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of BPH for each country, as well…
Clarivate Epidemiology's coverage of benign prostatic hyperplasia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of male lower urinary tract symptoms (LUTS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of male lower urinary tract symptoms (LUTS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of male lower urinary tract symptoms (LUTS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…